Treprostinil Palmitil ( DrugBank: Treprostinil )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 86 | 肺動脈性肺高血圧症 | 4 |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05649748 (ClinicalTrials.gov) | February 28, 2023 | 6/12/2022 | A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) | An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: Treprostinil Palmitil;Drug: Placebo | Insmed Incorporated | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2/Phase 3 | Japan |
| 2 | NCT05147805 (ClinicalTrials.gov) | August 24, 2022 | 24/11/2021 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: Treprostinil Palmitil;Drug: Placebo | Insmed Incorporated | NULL | Recruiting | 18 Years | 75 Years | All | 99 | Phase 2 | United States;Argentina;Australia;Austria;Belgium;Brazil;Denmark;Germany;Italy;Japan;Malaysia;Mexico;Philippines;Serbia;Spain;Switzerland;United Kingdom |
| 3 | JPRN-jRCT2071220033 | 02/08/2022 | 02/08/2022 | A Randomized, Double-Blind, Placebo-Controlled Study of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension | A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Experimental: Treprostinil Palmitil Inhalational Powder Participants will be administered TPIP once per day at a starting dose of 80 micrograms. Participants will be titrated to the highest tolerated dose for each individual participant of between 80 micrograms and 640 micrograms during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks. Placebo Comparator: Placebo Participants will be administered a placebo matching TPIP once per day for 16 weeks. | F Ismat | NULL | Recruiting | > 18age old | < 75age old | Both | 99 | Phase 2 | United States;Argentina;Australia;Mexico;Phillipines;Japan |
| 4 | NCT04791514 (ClinicalTrials.gov) | March 29, 2022 | 8/3/2021 | A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) | An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: Treprostinil Palmitil | Insmed Incorporated | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 2 | United States |